Literature DB >> 32585692

Double-edged sword of ALDH2 mutations: one polymorphism can both benefit and harm the cardiovascular system.

Francesca Bartoli-Leonard1, Louis Saddic2, Elena Aikawa1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32585692      PMCID： PMC7340353          DOI： 10.1093/eurheartj/ehaa444

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   35.855


× No keyword cloud information.
  14 in total

Review 1.  Thoracic and abdominal aortic aneurysms.

Authors:  Eric M Isselbacher
Journal:  Circulation       Date:  2005-02-15       Impact factor: 29.690

2.  The ALDH2 gene rs671 polymorphism is not associated with essential hypertension.

Authors:  Zhan-Ming Li; Chao-Yue Kong; Ke-Yu Sun; Li-Shun Wang
Journal:  Clin Exp Hypertens       Date:  2017-06-14       Impact factor: 1.749

Review 3.  Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease.

Authors:  Xiangwei Liu; Aijun Sun
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

4.  Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system.

Authors:  Antje D Ebert; Kazuki Kodo; Ping Liang; Haodi Wu; Bruno C Huber; Johannes Riegler; Jared Churko; Jaecheol Lee; Patricia de Almeida; Feng Lan; Sebastian Diecke; Paul W Burridge; Joseph D Gold; Daria Mochly-Rosen; Joseph C Wu
Journal:  Sci Transl Med       Date:  2014-09-24       Impact factor: 17.956

5.  Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndrome.

Authors:  Feng Xu; Yu Guo Chen; Li Xue; Rui Jian Li; He Zhang; Yuan Bian; Cheng Zhang; Rui Juan Lv; Jin Bo Feng; Yun Zhang
Journal:  J Cell Mol Med       Date:  2011-09       Impact factor: 5.310

6.  Associations between aldehyde dehydrogenase 2 (ALDH2) rs671 genetic polymorphisms, lifestyles and hypertension risk in Chinese Han people.

Authors:  Cong Ma; Bingxiang Yu; Weihua Zhang; Weimin Wang; Liping Zhang; Qiang Zeng
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

7.  Positive association between ALDH2 rs671 polymorphism and essential hypertension: A case-control study and meta-analysis.

Authors:  Yinyin Wu; Juntao Ni; Xiao Cai; Fuzhi Lian; Haiyan Ma; Liangwen Xu; Lei Yang
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

8.  Aldehyde dehydrogenase 2 Glu504Lys variant predicts a worse prognosis of acute coronary syndrome patients.

Authors:  Chang Pan; Yu Zhao; Yuan Bian; Rui Shang; Jia-Li Wang; Li Xue; Shu-Jian Wei; He Zhang; Yu-Guo Chen; Feng Xu
Journal:  J Cell Mol Med       Date:  2018-02-14       Impact factor: 5.310

Review 9.  Principles of miRNA-target regulation in metazoan models.

Authors:  Epaminondas Doxakis
Journal:  Int J Mol Sci       Date:  2013-08-07       Impact factor: 5.923

10.  miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer.

Authors:  Zhiyuan Lu; Qianting He; Jianfeng Liang; Wuguo Li; Qiao Su; Zujian Chen; Quan Wan; Xiaofeng Zhou; Laurel Cao; Jingjing Sun; Yu Wu; Lin Liu; Xinming Wu; Jinsong Hou; Keqian Lian; Anxun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-11       Impact factor: 8.886
View more
  2 in total

Review 1.  Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention.

Authors:  Jie Gao; Yue Hao; Xiangshu Piao; Xianhong Gu
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

2.  Macrophage ALDH2 (Aldehyde Dehydrogenase 2) Stabilizing Rac2 Is Required for Efferocytosis Internalization and Reduction of Atherosclerosis Development.

Authors:  Jian Zhang; Xiangkai Zhao; Yunyun Guo; Zhiping Liu; Shujian Wei; Qiuhuan Yuan; Haixia Shang; Wentao Sang; Sumei Cui; Tonghui Xu; Kehui Yang; Jialin Guo; Chang Pan; Jiali Wang; Jiaojiao Pang; Tianrui Han; Yuguo Chen; Feng Xu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-03-31       Impact factor: 10.514
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.